Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Kura Oncology, Inc.
KURA · SEC Filings
website
260
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatmen...
Price
7.57
Market Cap
673.43 M
Float
86.49 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about KURA
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Kura Oncology, Inc.
KURA · SEC Filings
86.49 M
Float
7.57
Price
673.43 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 4, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 7, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 1, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Kura Oncology Forms Subsidiary Caspian Therapeutics and Completes $50 Million Series A Financing for Cardiometabolic Diseases
Sep 9, 2026
8-K
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Sep 8, 2026
8-K
Kura Oncology Reports Second Quarter 2026 Financial Results and Corporate Update
Aug 12, 2026
8-K
Kura Oncology Updates Executive Employment Agreements
Jul 29, 2026
8-K
Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan
Jun 4, 2026
8-K
Kura Oncology Reports First Quarter 2026 Financial Results and KOMZIFTI™ Launch Progress
May 12, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B3
8,695,699 Shares
Feb 15, 2024
424B5
5,660,871 Shares of Common Stock
Jun 14, 2023
424B5
Common Stock
Jun 13, 2023
424B5
1,370,171 Shares of Common Stock
Nov 3, 2022
424B5
Common Stock-
Feb 24, 2022
424B5
8,110,000 Shares-
Dec 9, 2020
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 4, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 4, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 6, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 28, 2025
S-8
Common Stock
Jun 7, 2024
S-8
Registration
Feb 27, 2024
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 26, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 10, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 11, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 11, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 12, 2024
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
BlackRock, Inc. (Filed by)
Oct 27, 2026
4
Bair Teresa Brophy (Reporting)
Sep 29, 2026
4
FORD KATHLEEN (Reporting)
Sep 29, 2026
4
Leoni Mollie (Reporting)
Sep 29, 2026
4
DOYLE THOMAS JAMES (Reporting)
Sep 29, 2026
4
Powl Brian T. (Reporting)
Sep 29, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
LETTER
Form UPLOAD - SEC-generated letter
Feb 29, 2024
EFFECT
Form EFFECT - Notice of Effectiveness
Feb 15, 2024
CORRESP
Form CORRESP - Correspondence
Feb 14, 2024
CORRESP
Form CORRESP - Correspondence
Feb 13, 2024
CT ORDER
Form CT ORDER - Confidential treatment order
Feb 21, 2023
EFFECT
Form EFFECT - Notice of Effectiveness
Aug 19, 2020
